JP7702150B2 - Ｓｔａｔ３のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤 - Google Patents

Ｓｔａｔ３のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤 Download PDF

Info

Publication number
JP7702150B2
JP7702150B2 JP2022533676A JP2022533676A JP7702150B2 JP 7702150 B2 JP7702150 B2 JP 7702150B2 JP 2022533676 A JP2022533676 A JP 2022533676A JP 2022533676 A JP2022533676 A JP 2022533676A JP 7702150 B2 JP7702150 B2 JP 7702150B2
Authority
JP
Japan
Prior art keywords
stc1
preventive
ace2
therapeutic agent
tmprss2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022533676A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022004054A1 (https=
Inventor
眞也 大河内
雅彦 兼平
克典 岡田
一 黒澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Original Assignee
Tohoku University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC filed Critical Tohoku University NUC
Publication of JPWO2022004054A1 publication Critical patent/JPWO2022004054A1/ja
Priority to JP2025085915A priority Critical patent/JP2025109968A/ja
Application granted granted Critical
Publication of JP7702150B2 publication Critical patent/JP7702150B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2022533676A 2020-06-30 2021-03-01 Ｓｔａｔ３のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤 Active JP7702150B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025085915A JP2025109968A (ja) 2020-06-30 2025-05-22 Ｓｔａｔ３のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020112680 2020-06-30
JP2020112680 2020-06-30
PCT/JP2021/007780 WO2022004054A1 (ja) 2020-06-30 2021-03-01 Ｓｔａｔ３のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025085915A Division JP2025109968A (ja) 2020-06-30 2025-05-22 Ｓｔａｔ３のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤

Publications (2)

Publication Number Publication Date
JPWO2022004054A1 JPWO2022004054A1 (https=) 2022-01-06
JP7702150B2 true JP7702150B2 (ja) 2025-07-03

Family

ID=79315687

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022533676A Active JP7702150B2 (ja) 2020-06-30 2021-03-01 Ｓｔａｔ３のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤
JP2025085915A Pending JP2025109968A (ja) 2020-06-30 2025-05-22 Ｓｔａｔ３のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025085915A Pending JP2025109968A (ja) 2020-06-30 2025-05-22 Ｓｔａｔ３のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤

Country Status (5)

Country Link
US (1) US20230201310A1 (https=)
EP (1) EP4194004A4 (https=)
JP (2) JP7702150B2 (https=)
CN (1) CN115835879A (https=)
WO (1) WO2022004054A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114732831B (zh) * 2022-04-25 2023-06-23 齐鲁理工学院 斯钙素-1作为调节肿瘤微环境的标志物的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008681A1 (ja) 2011-07-09 2013-01-17 国立大学法人東北大学 線維症予防又は治療用医薬組成物
JP2016520583A (ja) 2013-05-10 2016-07-14 オルフス ユニバーシテト パッパリシンレギュレーター

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2387685A1 (en) * 1999-10-27 2001-05-03 Human Genome Sciences, Inc. Stanniocalcin proteins and nucleic acids and methods based thereon
US8759298B2 (en) * 2010-05-03 2014-06-24 Scott & White Healthcare Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008681A1 (ja) 2011-07-09 2013-01-17 国立大学法人東北大学 線維症予防又は治療用医薬組成物
JP2016520583A (ja) 2013-05-10 2016-07-14 オルフス ユニバーシテト パッパリシンレギュレーター

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BONFANTE, S. et al.， Stanniocalcin 1 Inhibits the Inflammatory Response in Microglia and Protects Against Sepsis-Associa，Neurotoxicity Research，2020年10月06日，Vol. 39，pp. 119-132
Cytokine: X，2020年05月14日，Vol. 2, No. 2, 100029，pp. 1-7，DOI: 10.1016/j.cytox.2020.100029
Free Radical Biology and Medicine，2014年，Vol. 71，pp. 321-331，DOI: 10.1016/j.freeradbiomed.2014.03.034
HUANG, L. et al.，Stanniocalcin-1 inhibits thrombin-induced signaling and protects from bleomycin-induced lung injury，SCIENTIFIC REPORTS，2015年，Vol. 5，article number 18117, pp. 1-13
Innovative Medicine，2015年，pp. 131-147，DOI: 10.1007/978-4-431-55651-0_11
WU, Y. et al.，Upregulation of stanniocalcin‐1 inhibits the development of osteoarthritis by inhibiting survival a，Journal of Cellular Biochemistry，2019年，Vol. 120，pp. 9768-9780，DOI: 10.1002/jcb.28257
ZHAO, J. et al.，Stanniocalcin 2 Ameliorates Hepatosteatosis Through Activation of STAT3 Signaling，Frontiers in Physiology，2018年，Vol. 9, Article 873，pp. 1-8
ウイルス，Vol. 69, No. 1，2019年，pp. 61-72，<URL: http://jsv.umin.jp/journal/v69-1pdf/virus69-1_061-072.pdf>

Also Published As

Publication number Publication date
US20230201310A1 (en) 2023-06-29
JP2025109968A (ja) 2025-07-25
CN115835879A (zh) 2023-03-21
EP4194004A1 (en) 2023-06-14
WO2022004054A1 (ja) 2022-01-06
TW202207972A (zh) 2022-03-01
JPWO2022004054A1 (https=) 2022-01-06
EP4194004A4 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
Gotts et al. Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy
CN114786659A (zh) 用于治疗汉坦病毒感染的mek抑制剂
KR102174576B1 (ko) 바이러스 질환 치료에서의 ｍｅｋ 억제제
Tian et al. Novel effect of methionine enkephalin against influenza A virus infection through inhibiting TLR7-MyD88-TRAF6-NF-κB p65 signaling pathway
JP2025109968A (ja) Ｓｔａｔ３のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤
EP4487870A2 (en) Vidofludimus for use in the treatment or prevention of viral diseases
US20230058134A1 (en) Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
US12083165B2 (en) Thymosin alpha 1 for use in treatment of cystic fibrosis
US20230293565A1 (en) Use of wnt/beta-catenin pathway inhibitors to block replication of sars-cov-2 and other pathogenic viruses
KR102843222B1 (ko) 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도
JP2023530431A (ja) コロナウイルスを治療するための化合物および方法
CN101559049B (zh) 肝纤维化抑制剂
He et al. C-fiber degeneration enhances alveolar macrophage-mediated IFN-α/β response to respiratory syncytial virus
WO2021129890A1 (zh) 阻断微生物感染、降低胆固醇、防治相关肿瘤的药物及其应用
US20230270826A1 (en) Antiviral use of liraglutide and gefitinib
TWI916376B (zh) Stat3之磷酸化抑制劑、自體免疫疾病及冠狀病毒傳染病之預防或治療劑
KR20210023710A (ko) 니클로사마이드 지연방출 조성물 및 이의 항바이러스 용도
EP4333867B1 (en) Peptides inhibiting covid-19
Oba et al. Iguratimod, a promising therapeutic agent for COVID-19 that attenuates excessive inflammation in mouse models
KR20220033450A (ko) 니클로사마이드를 포함하는 항인플루엔자 바이러스용 조성물
WO2021209620A1 (en) Cysteine protease inhibitors for use in the prevention and/or treatment of coronavirus
WO2021181279A1 (en) Compositions and methods for treating covid-19 infections and/or symptoms thereof
EP4248961A1 (en) Antiviral composition for sars-cov-2 and hcov-oc43 comprising rhein, meclofenamic acid, or a combination thereof
CN120815076A (zh) Sal-0133在制备预防和/或治疗人鼻病毒感染的药物中的应用
KR20190135296A (ko) 돼지생식기호흡기증후군 바이러스 Ｎｓｐ１ 단백질을 유효성분으로 포함하는 면역증강용 조성물

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250616

R150 Certificate of patent or registration of utility model

Ref document number: 7702150

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150